source
- Acadia’s Alzheimer’s psychosis drug misses primary goal but advances on secondary dataAcadia Pharmaceuticals reported that its investigational drug remlifanserin failed to meet the primary endpoint in the Phase 2 portion of the RADIANT trial for Alzheimer’s disease psychosis. The t…
- Kyverna reports durable responses in early cell therapy trial for autoimmune diseaseKyverna Therapeutics announced new data from its cell therapy candidate targeting an autoimmune condition, marking progress toward a potential first‑in‑class product. The results showed that a not…